{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Keytruda&page=2", "query": { "intervention": "Keytruda", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Keytruda&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-02T18:26:50.459Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03371979", "title": "Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Pegzilarginase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aeglea Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-12-21", "completion_date": "2021-01-01", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 21, "location_summary": "Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orange City", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371979" }, { "nct_id": "NCT04938817", "title": "Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "coformulation pembrolizumab/quavonlimab", "type": "BIOLOGICAL" }, { "name": "lenvatinib", "type": "DRUG" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "coformulation favezelimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "R-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2021-08-19", "completion_date": "2029-12-10", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 12, "location_summary": "Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04938817" }, { "nct_id": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastroesophageal Junction Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "Spevatamig (PT886)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2023-03-15", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05482893" }, { "nct_id": "NCT03219450", "title": "A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphocytic Leukemia" ], "interventions": [ { "name": "NeoVax", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-08-18", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219450" }, { "nct_id": "NCT06046274", "title": "GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Acasunlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2023-10-01", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 2, "location_summary": "Orlando, Florida • New Brunswick, New Jersey", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06046274" }, { "nct_id": "NCT03732950", "title": "Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2019-03-06", "completion_date": "2025-03-06", "has_results": false, "last_update_posted_date": "2024-04-15", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 3, "location_summary": "Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732950" }, { "nct_id": "NCT06780111", "title": "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "I-DXd", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2025-07-30", "completion_date": "2032-01-04", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780111" }, { "nct_id": "NCT03184571", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer Metastatic", "NSCLC Stage IV", "Adenocarcinoma of Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Bemcentinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BerGenBio ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2017-10-02", "completion_date": "2022-10-27", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Milwaukee, Wisconsin", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184571" }, { "nct_id": "NCT03504163", "title": "Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab (MK-3475)", "type": "DRUG" }, { "name": "Bacillus Calmette-Guérin (BCG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2018-06-27", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504163" }, { "nct_id": "NCT04634877", "title": "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiotherapy (EBRT)", "type": "RADIATION" }, { "name": "Cisplatin (as radiosensitizer)", "type": "DRUG" }, { "name": "Brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 990, "start_date": "2021-01-10", "completion_date": "2026-09-15", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-02T18:26:50.459Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634877" } ] }